

INDEX

Note: Page numbers in *italics* indicate figures;
page numbers followed by t indicate tables.

- Acebutolol, 39-40, *41*
Acetylcholine, 23, *24*
Adenoma, pituitary, 68
Adrenergic nerves, 23, *24*
Advanced glycation end-products, 38-39
Afferent pathways, 53
Age-related erectile dysfunction, 10-12, *11*, 12t
 advanced glycation end-products in, 38-39
 concern over, 33
 penile arterial revascularization and, 125
 penile biothesiometry and, 52, 53t
 sildenafil for
 effectiveness of, 76, 88, 101
 metabolism of, 76
 popularity of, 96-97
 tunica albuginea weakening and, 36
Alcohol
 erectile dysfunction related to, 40t
 reversal of, 69
 sildenafil and, 101
Alpha-adrenergic blockers, 39
Alprostadil (prostaglandin E₁)
 injected
 action mechanism of, 111
 corporal fibrosis from, 113
 dosage of, 112-113
 in intracavernosal pharmacologic testing, 55-56
 intraurethral
 action mechanism of, 114
 administration of, 114-116, *115*
 adverse effects of, 118, 119t
 contraindications to, 116
 dosage of, 116, 117t
 effectiveness of, 116, 117t
 indications for, 115
Alzheimer's disease, 34
Amlodipine, 39-40, *41*
Amyl nitrate or nitrite (poppers), 99t
Anatomy of penis. See *Penis, anatomy of; Peyronie's disease.*
Androgens. See also *Testosterone therapy.*
 libido and, 37
Anger, 12, 12t
Angina, 42
Angiotensin-converting enzyme (ACE) inhibitors, 39, 40t, 100
Antiandrogens, 40t, 41
Antiarrhythmic drugs, 39-40, 40t
Antidepressant drugs, 39-41, 40t
 dysfunction from, 132
 sildenafil with, 40t, 79, 100
Antihypertensive drugs, 39-40, 40t, *41*
 sildenafil with, 79
Antipsychotic drugs, 40-41
 sildenafil with, 79
Anxiety-related erectile dysfunction, 33, 42, 56
Aortic aneurysm, 68
Apomorphine, 102-103, 137
Arterial blood supply, penile, 17, *18*
Arterial disease, 36
Arterial insufficiency, 42
Arterial revascularization
 complications of, 127
 procedures in, 125, *126*, 127
Arteriogenic erectile dysfunction, 32
 classification of, 36
 initial symptoms of, 35
 progression of, 35-36
 risk factors for, 35
 treatment of, 36
Arteriolar smooth muscle, erection and, 22-23
Arteriosclerosis, 41
Aspirin, 101
Atherosclerosis, 35
 penile arterial revascularization and, 125
 sildenafil in, 133
Autonomic impotence, 33. See also *Neurogenic erectile dysfunction.*
Autonomic nervous system, in penis, 20, 20-21
Back pain, 89
Beta blockers, 39, 40t, 100
Biothesiometry, penile, 52, 53t
Bladder dysfunction, 54
Bladder outlet obstruction, testosterone therapy and, 70
Bleeding disorders, sildenafil in, 100
Blood supply of penis
 arterial, 17, *18*, 23
 venous, 19, 20, 62-63, 63
Blunt trauma, perineal or pelvic, 35-36, 68
Body image, 33, 42
Brain injury or tumor, 34

Buck's fascia, 15, 16, 17
 Bupropion, 132
 Cachexia, 42
 Calcium channel blockers, 39, 40t, 100
 Calcium homeostasis, 22
 Cardiovascular disease
 sildenafil in, 78-79, 96, 97
 treated, 12, 12t
 Cardiovascular system
 sexual activity and, 94, 98
 sildenafil effects on, 92-95, 94t
 Cascade theory of erection, 28, 29, 29
 Castration, testosterone level after, 37
 Causes of erectile dysfunction, 9-10, 32. See also specific
 etiology, eg, *Neurogenic erectile dysfunction*.
 mixed, 9-10
 sildenafil effectiveness in, 77, 84
 Cavernosal artery systolic pressure, 61
 Cavernosal (venogenic) erectile dysfunction, 32
 classification of, 36-37
 occlusion and, 37, 38
 Cavernosal pharmacologic testing, 55-56
 Cavernosometry-cavernosography, 57, 59-60, 61-63, 62-63
 Cerebrovascular accident, 34
 Chlorthalidone, 39-40, 41
 Cholesterol level, 12, 12t, 34
 Cholinergic nerves, 23, 24
 Cimetidine, 40t
 sildenafil and, 95, 100
 Cirrhosis, 42
 Classification of erectile dysfunction, 9-10, 32
 Clinical assessment of erectile dysfunction
 algorithm for, 45, 46-47
 endocrine tests in, 63-64
 intracavernosal pharmacologic tests in, 55-56
 laboratory tests in, 51-52
 medical history in, 50
 neurologic tests in, 52-54, 53t
 nocturnal penile tumescence and rigidity tests in, 54-55, 76-77
 physical examination in, 50-51
 psychological tests in, 56
 psychosocial history in, 49-50
 referral indicators in, 67-68
 sexual history in, 45, 48t, 49
 vascular tests in, 56-57
 color-flow Doppler ultrasonography in, 57, 57, 58
 dynamic infusion cavernosometry and cavernosography in,
 57, 59-60, 61-63, 62-63
 Cocaine, 40t, 41
 Color-flow duplex ultrasonography and Doppler analysis, 57, 57-58
 Colostomy, 42
 Congenital malformation, venous, 36
 Congestive heart failure, 94
 Coronary artery disease, 78-79, 94
 Corpora cavernosa, anatomy of, 15, 16
 Corpus spongiosum, 15, 16, 17
 Coumadin, 106
 Curvature of penis, 68. See also *Peyronie's disease*.
 Cytochrome P450, sildenafil metabolism and, 74, 76, 100
 Definition of erectile dysfunction, 9
 Dehydroepiandrosterone (DHEA) sulfate level, 12, 12t
 Depression, 12, 12t, 33
 sildenafil in, 78-79
 Detumescence
 in malleable prosthesis, 123
 norepinephrine and, 26
 Diabetes mellitus, 10, 35, 42
 aging in, 39
 apomorphine in, 103
 glycemic control in, 69
 penile arterial revascularization and, 125
 sildenafil in, 78-79, 86, 96, 132
 smooth muscle atrophy in, 37
 testing for, 51
 treated, 12, 12t
 Diabetic retinopathy, 96, 132
 Diagnosis of erectile dysfunction. See *Clinical assessment of
 erectile dysfunction*.
 Diarrhea, 90t
 Digoxin, 40, 40t
 Disc herniation, spinal, 34
 Diuretics, 39, 40t
 sildenafil with, 79, 100
 Dizziness
 intraurethral alprostadil and, 118, 119t
 sildenafil-related, 90t, 92
 Doppler ultrasound with color-flow duplex ultrasonography, 57,
 57-58
 Doxazosin, 39-40, 41
 Drug-related erectile dysfunction, 39-41, 40t, 41
 in medical history, 50
 treatment of, 68, 132
 Dyspepsia, 89, 90t-91t, 92
 Dyspnea, 42
 Economic status, 13

- Efferent pathways
 - in neurologic testing, 54
 - nocturnal tumescence and, 54
- Ejaculation
 - dysfunctional, 53
 - premature, 10
- Emotional stress-related erectile dysfunction, 56
- Emphysema, 42
- Enalapril, 39-40, 41
- Endocrine disorders, in medical history, 50
- Endocrinologic erectile dysfunction, 32
 - diagnosis of, 63-64
 - disorders associated with, 37-38
 - incidence of, 37
 - treatment of, 69, 133-134
- Endothelial tissue
 - cocaine-related damage to, 41
 - dysfunctional, 36
 - in venous occlusion, 37, 38
- Endothelin-1, erection and, 26
- Erection. *See Penile erection.*
- Erythritol tetranitrate (cardilate), 99t
- Erythromycin, 95, 100-101
- Fear-related erectile dysfunction, 56
- Females
 - sexual arousal disorder in, 97, 137
 - sildenafil for, 97
- Fetus, sildenafil exposure to, 74
- Fibrosis, cavernosal, 36
- Filling phase of erection, 28, 29
- Flaccid phase of erection, 27, 28, 29
- Flu-like symptoms
 - intraurethral alprostadil and, 119t
 - sildenafil-related, 89-90
- Flushing, 89, 90t-91t, 92
- Follicle-stimulating hormone, 51, 64
- Fracture, penile, 37
- Gap junctions
 - dysfunctions of, 36
 - in erection, 29
- Genitalia
 - examination of, 51
 - stimulation of, in reflexogenic erection, 31
- Geriatric population. *See Age-related erectile dysfunction.*
- Glans penis, 15, 16
- Gonadotropin-releasing hormone, 37
- Gonadotropin-releasing hormone agonists, 40t

- Guanosine triphosphate, 24, 25, 73, 75
- Guilt-related erectile dysfunction, 56
- Hair, on body and face, 51
- Headache
 - intraurethral alprostadil and, 119t
 - sildenafil-related, 89, 90t-91t, 92
- Heart failure, 42
- Helicine arteries, 23
- Hematoma prevention, 113
- Hepatic cirrhosis, 42
- Hepatic insufficiency, 76, 101
- Heroin, 40t
- High density lipoprotein cholesterol level, 12, 12t
- Histamine blockers, 40t
- History taking
 - medical, 50, 136
 - psychosocial, 49-50
 - sexual, 45, 48t, 49
 - with sexual partner, 49-50
- Hormone replacement therapy, 133-134
- Hypercholesterolemia, 96
- Hyperlipidemia, 35
 - penile arterial revascularization and, 125
 - sildenafil in, 78, 133
- Hyperprolactinemia, 37
 - reversing effects of, 69
- Hypertension, 12, 35
 - sildenafil in, 78-79, 96, 133
- Hyperthyroidism, 38
- Hyperviscosity syndrome, 116
- Hypogonadism
 - laboratory testing in, 51
 - nocturnal erectile activity in, 37
 - secondary, 68
 - treatment of, 69
- Hypotension
 - intraurethral alprostadil and, 116, 119t
 - from sildenafil and nitrates, treatment of, 98
- Hypothyroidism, 38
- Ileostomy, 42
- Innervation of penis, 20, 21, 22
- International Index of Erectile Function (IIEF)
 - patient selection for
 - age range of, 77
 - number of, 77
 - risk factors in, 78
 - underlying dysfunction etiology in, 77

International Index of Erectile Function (IIEF) (*continued*)
 questionnaire for, 78
 sildenafil effectiveness measured by, 78-79, 84
 Intracavernosal pharmacologic testing, 55-56
 Intracavernosal pharmacotherapy
 adverse effects of, 113-114
 discontinuation of, 114
 dosage and administration in, 112, 112-113
 drugs for, 111-112
 indications for, 113
 hematoma prevention in, 113
 pain in, 112-113
 return of spontaneous erection after, 114
 Intraurethral alprostadil
 action mechanism of, 114
 administration of, 114-116, 115
 adverse effects of, 118, 119t
 contraindications to, 116
 dosage of, 116, 117t
 effectiveness of, 116, 117t
 indications for, 115
 Irradiation, pelvic, 35
 Isosorbide dinitrate, 99t
 Isosorbide dinitrate/phenobarbital (Isordil), 99t
 Isosorbide mononitrate, 99t
 Itraconazole, 100, 101
 Ketoconazole, 40t, 100, 101
 Kidney transplantation, 42
 Laboratory testing, 51-52
 Latent phase of erection, 28, 29
 Leukemia, sildenafil in, 97-98
 Lipid profile, 51
 Lue's combined injection and stimulation (CIS) test, 55
 Lumbosacral disc disease, 68
 Luteinizing hormone, 51, 64
 Madonna-prostitute syndrome, 33
 Marijuana, 40t, 41
 Massachusetts Male Aging Study (MMAS), 10-12, 11, 12t, 97
 Masturbation, erection in, 56
 Medical history, 50
 Medication use, in medical history, 50
 Mixed etiology of erectile dysfunction, 9-10
 sildenafil effectiveness in, 77, 84
 Molecular basis of erectile dysfunction, 137
 Multiple myeloma
 intraurethral alprostadil in, 116
 sildenafil in, 97, 98

Multiple sclerosis, 34
 Muscle, smooth, penile, 22-23, 24
 Muscle relaxants, 50
 in color-flow duplex ultrasonography and Doppler analysis, 57, 57-58
 Myocardial infarction, 42
 sildenafil-related, 93-94, 94t
 Nasal congestion, 89, 91t, 92
 National Health and Social Life Survey, 13
 Neurogenic erectile dysfunction, 32
 alprostadil/phentolamine injection for, 113
 brain lesions in, 34
 disorders associated with, 33
 intracavernosal pharmacologic test results in, 55
 peripheral neuropathy in, 35
 treatment of
 intracavernosal injection in, 133
 muscle relaxants in, 50
 sildenafil in, 133
 vasoactive agents in, 50
 Neurologic disorders
 intraurethral alprostadil and, 118, 119t
 in medical history, 50
 testing for, 52
 Neurosurgery, indications for, 68
 Neurotransmitters
 erection and, 26
 inadequate release of, 36
 Neurovascular disorder, 10
 Nitrates
 phentolamine and, 104
 sildenafil interaction with, 98, 99t
 Nitric oxide, erection and, 23-24, 25
 Nitroglycerin, 99t
 Nocturnal erectile activity
 in hypogonadism, 37
 testing of, 54-55
 Nonadrenergic-noncholinergic (NANC) nerves
 erection and, 25
 trabecular smooth muscle tone and, 23, 24
 Norepinephrine, 26
 Obesity, 96
 Obsessive-compulsive personality, 33
 Oedipus complex, 106
 Onset of erectile dysfunction, 45
 Organic erectile dysfunction, 9
 intracavernosal pharmacologic test results in, 55

Organic erectile dysfunction (*continued*)
 sildenafil effectiveness in, 77, 84
 treatment of, 136

Papaverine
 injected, 111
 in intracavernosal pharmacologic testing, 55, 59

Parasympathetic penile nerves, 20, 21

Parental inhibition-related erectile dysfunction, 56

Parkinson's disease, 34

Partner. See *Sexual partner*.

Patient consultation
 referral in, 67-68
 with test results and treatment options, 67

Pelvic irradiation, 35

Pelvic steal syndrome, 36, 60, 61

Pelvic trauma, 35-36
 erectile dysfunction treatment after, 68, 134-135

Penile erection
 cascade theory of, 29
 full, 27, 28, 29
 mechanism of, 27
 nitric oxide in, 23-24, 25
 norepinephrine in, 26
 phases of, 28, 29, 29
 rigid, 28, 29, 29
 skeletal, 28, 29
 smooth muscle in, 22-23, 24

Penile injection therapy, 56

Penile prostheses
 advantages of, 122
 disadvantages of, 121
 history of, 121
 indications for, 132
 inflatable, 122, 124, 125
 malleable/positional rod, 122, 123
 in neurogenic dysfunction, 133

Penile trauma, 68

Penile tumor, 37

Penis
 anatomy of, 15, 16, 17
 arterial blood supply of, 17, 18
 deformities of
 dysfunction treatment in, 135
 intraurethral alprostadil in, 116
 sildenafil in, 98
 deformities of. See also *Peyronie's disease*.
 correctible, 70
 curvature as, 68

Penis (*continued*)
 innervation of, 20, 21, 22
 smooth muscle of, 22-23, 24
 tactile sensation in, 53
 venous drainage of, 19, 20, 62-63, 63

Pentaerythritol tetranitrate, 99t

Pentoside, 39

Peptic ulceration, 100

Performance anxiety, 10, 49

Perineal trauma, 35
 treatment of, 68, 134-135

Peripheral neuropathy, 35

Peripheral vascular disease, sildenafil in, 79

Peyronie's disease, 36-37
 diagnosis of, 51
 dysfunction treatment in, 135
 inflatable penile prosthesis for, 122
 reconstructive surgery for, 68

Phentolamine, 103-104
 future of, 137
 in infusion cavernosometry and cavernosography, 59
 injected
 action mechanism of, 111
 dosage of, 112-113

Phobias, 33

Phosphodiesterase type 5
 erection and, 24, 25
 side effects of, 89
 sildenafil and, 73-75, 75

Phosphodiesterase type 6, visual effects of, 95

Physical attraction, lack of, 33

Physical examination, 50-51

Pituitary adenoma, 68

Polycythemia, 116

Pregnancy, fear of, 10

Prevalence of erectile dysfunction, 10-13, 11, 12t

Priapism, 37
 conditions predisposing to, 97, 98
 injected alprostadil and, 113
 in intracavernosal pharmacologic testing, 55
 intraurethral alprostadil and, 116
 sildenafil and, 96-97

Primary erectile dysfunction, 49

Process of Care Model for the Evaluation and Treatment of
 Erectile Dysfunction, 45, 46-47, 67-68, 73, 111, 121

Prolactin level, 37-38, 51

Prostaglandin, erection and, 26

Prostaglandin E₁. See *Alprostadil (prostaglandin E₁)*.

Prostate

- cancer of. See also *Prostatectomy*.
 - impotence after, 41, 54
 - testosterone therapy and, 70
 - size and consistency of, 51
- Prostate specific antigen, 51
- Prostate-specific antigen, determination of, before testosterone therapy, 69-70
- Prostatectomy, radical, 10
 - apomorphine after, 103
 - injection therapy after, 134
 - sildenafil after, 78-79, 87-88, 134
- Prostglandin E1. See *Alprostadil*.
- Prosthetic penis. See *Penile prostheses*.
- Proteins, contractile, 22
- Psychogenic erectile dysfunction
 - brain messages in, 33
 - causes of, 10, 56
 - incidence of, 33
 - indicators of, 10, 49
 - intracavernosal pharmacologic test results in, 55
 - physiology of, 31, 32
 - sildenafil effectiveness in, 77, 84
 - tests for, 56
 - treatment of, 131
 - psychosexual, 106-107
- Psychosexual therapy, 49, 73, 106-107
 - for psychogenic dysfunction, 131
- Psychosocial history, 49-50. See also *Sexual history*.
 - reversing effects of, 68
- Pulmonary emphysema, 42
- Pyrraline, 39
- Rash, 90t
- Rectal cancer, impotence after, 54
- Rectal examination, 51
 - before testosterone therapy, 69-70
- Referral to specialist, 67-68
- Reflexogenic erection, 31
- Relationship conflict, 10
- Religious inhibition, 33, 56
- Renal disease, 39, 42
- Renal insufficiency, 76, 101
- Respiratory system, 119t
- Respiratory tract infection, 89, 92
- Retinitis pigmentosa, 100
- Revascularization, 68
- Rigidity, 28, 29, 29
 - nocturnal, 37, 54-55
- RigiScan Plus Rigidity Assessment System, 55
 - sildenafil effectiveness measured on, 76-77
- Scar tissue formation, 113
- Scleroderma, 37
- Secondary erectile dysfunction, 49
- Selective serotonin reuptake inhibitors, 40t, 100
- Sensory deficit erectile dysfunction, 53
- Sensory impotence, 33. See also *Neurogenic erectile dysfunction*.
- Sensory penile nerves, 20, 21
- Severe erectile dysfunction, sildenafil for, 88
- Sex characteristics, secondary, 51
- Sexual arousal disorder, female, 97
- Sexual desire
 - low, 10
 - sildenafil and, 79, 84
- Sexual history. See also *Psychosocial history*.
 - distinguishing erectile dysfunction from other sexual problems in, 45
 - dysfunction onset in, 45
 - patient questionnaire in, 48t
 - primary *versus* secondary dysfunction in, 49
 - psychogenic indicators in, 49
- Sexual inhibition, 10
- Sexual partner
 - couple therapy for, 68
 - discord with, 49
 - sildenafil exposure to, 74
 - sildenafil questionnaire for, 77, 88
 - therapist meeting with, 49-50
- Sexual phobias, 33
- Sexual preference conflicts, 10
- Sexual techniques, 49
- Sexually transmitted disease, fear of, 10
- Sickle cell anemia
 - intraurethral alprostadil in, 116
 - sildenafil in, 97-98
- Sildenafil (Viagra)
 - for atherosclerotic-related dysfunction, 133
 - contraindications to, 98, 99t, 100
 - death from, 96
 - dosage of, 74, 101
 - drug interactions with, 100-101
 - effectiveness of, 74
 - after radical prostatectomy, 78-79, 87-88
 - after spinal cord injury, 78-79, 86-87

Sildenafil (Viagra), effectiveness of (*continued*)
 age and, 76, 88, 101
 in diabetes mellitus, 78-79, 86
 diary log of, 77, 84-86, 85
 lag time until, 74, 101
 measured by Global Efficacy Question, 77, 84-86, 85
 measured by International Index of Erectile Function (IIEF).
 See *International Index of Erectile Function (IIEF)*.
 measured by RigiScan Plus Rigidity Assessment System, 55, 76-77
 in mixed erectile dysfunction, 77, 84
 in organic erectile dysfunction, 77, 84
 partner questionnaire in, 77
 in psychogenic erectile dysfunction, 77, 84
 excretion of, 76
 for females, 97
 food intake with, 74
 in geriatric population, 76
 hepatic insufficiency and, 76, 101
 metabolism of, 76
 nitrate interaction with, 98, 98t
 overdose of, 74
 partner or fetal exposure to, 74
 pharmacokinetics of, 73-74, 75, 76
 popularity of, 96
 patient age and, 97
 pre-existing medical conditions and, 78-79
 for psychogenic dysfunction, 131
 renal insufficiency and, 76, 101
 safety of
 fixed dose studies of, 90, 91t, 92
 flexible dose studies of, 89-90, 90t
 long-term open-label studies of, 92-96, 94t
 post-FDA approval field experience with, 96-97
 sexual desire and, 79, 84
 side effects of, 89-90, 90t-91t, 92
 cardiovascular, 92-96, 94t
 visual, 90t-91t, 92, 95-96
 third-party reimbursement for, 97-98
 trazodone with, 132
 Skeletal erection, 28, 29
 Sleep, erections during, 37, 54-55
 Smoking, 12, 12t, 35
 penile arterial revascularization and, 125
 reversing effects of, 69
 sildenafil and, 96, 133

Smooth muscle
 atrophy of, 37
 penile, 22-23, 24
 Spina bifida, 34
 Spinal cord injury
 apomorphine in, 103
 erectile incidence after, 33-34
 location of, 34
 priapism in, 97
 sildenafil in, 78-79, 86-87
 Spinal disc herniation, 34
 Spironolactone, 40t
 Steal syndrome, pelvic, 36, 60, 61
 Stroke, 34
 Sympathetic outflow, excessive, 31
 Sympathetic penile nerves, 20, 20-21
 Syringomyelia, 34
 Tabes dorsalis, 34
 Tactile sensation, in penis, 53
 Testosterone level, 51
 after castration, 37
 in endocrinologic erectile dysfunction, 64
 Testosterone therapy, 133-134
 contraindications to, 70
 indications for, 69-70
 tests before initiation of, 69
 Thrombocytopenia, 116
 Thyroid function profile, 51
 Tolbutamine, 100
 Trabecular smooth muscle
 erection and, 22
 neuroeffector systems and, 23, 24
 Transurethral alprostadil. See *Intraurethral alprostadil*.
 Trauma, perineal or pelvic, 33, 35-36
 dysfunction treatment after, 68, 134-135
 Trazodone, 73, 102
 for drug-related dysfunction, 132
 sildenafil with, 132
 Treatment of erectile dysfunction
 after radical prostatectomy, 134
 after trauma, 134-135
 algorithm for, 46-47
 anatomic deformity and, 70, 98, 116, 135
 atherosclerotic disease-related, 132-133
 in diabetes, 78-79, 86, 96, 103-132
 drug-related, 68, 132
 endocrinologic, 69, 133-134

Treatment of erectile dysfunction (*continued*)

- future directions in, 137
 - intracavernosal pharmacotherapy in
 - adverse effects of, 113-114
 - discontinuation of, 114
 - dosage and administration in, 112, 112-113
 - drugs for, 111-112
 - hematoma prevention in, 113
 - indications for, 113
 - pain in, 112-113
 - return of spontaneous erection after, 114
 - intraurethral alprostadil in
 - action mechanism of, 114
 - administration of, 114-116, 115
 - adverse effects of, 118, 119t
 - contraindications to, 116
 - dosage of, 116, 117t
 - effectiveness of, 116, 117t
 - indications for, 115
 - motivation for, 49
 - neurogenic, 133
 - organic, 136
 - patient education in, 67
 - penile injection therapy in, 56
 - penile prostheses in. *See Penile prostheses.*
 - pharmaceutical
 - apomorphine in, 102-103
 - muscle relaxants in, 50
 - phentolamine in, 103-104
 - sildenafil in. *See Sildenafil (Viagra).*
 - trazodone in, 73, 102
 - vasoactive agents in, 50
 - yohimbine in, 73, 101-102
 - psychogenic, 131
 - psychosexual therapy in, 49, 73, 106-107
 - referral to specialist in, 67-68
 - vacuum constriction devices in, 73, 104, 105, 106
 - vascular surgery in
 - arterial revascularization as, 125, 126, 127, 135
 - contraindications to, 125
 - indications for, 125
 - venous ligation as, 127, 128-129
- Treatment of Mild Hypertension Study (TOMHS), 39-40, 41
- Tricyclic antidepressants, 40t, 100
- dysfunction from, 132
- Tumescence, 27, 29
- in malleable prosthesis, 123
 - nocturnal, 54-55

Tumors

- brain, 34
 - spinal, 34
- Tunica albuginea
- anatomy of, 15, 16
 - distortion of, 36
 - in erection, 27
 - pyrroline in, 39
- Ulcers, peptic, 100
- Urinary tract infection, 90t
- Urogenital system, intraurethral alprostadil and, 118, 119t
- Vacuum constriction devices, 104, 105, 106
- Vascular disorders, in medical history, 50
- Vascular surgery
- arterial revascularization as, 125, 126, 127
 - contraindications to, 125
 - indications for, 68, 70, 125
 - venous ligation as, 127, 128-129
- Vascular testing
- color-flow duplex ultrasonography and Doppler analysis in, 57, 57-58
 - indications for, 56-57
- Vasoactive agents, 50
- in intracavernosal pharmacologic testing, 55-56
- Venogenic erectile dysfunction. *See Cavernosal (venogenic) erectile dysfunction.*
- Venous drainage, penile, 19, 20, 62-63, 63
- Venous ligation
- indications for, 127
 - procedures in, 128-129
- Venous occlusion, 37, 38
- diagnosis of
- cavernosometry and cavernosography in, 55, 57, 59-60, 61-63, 62-63
 - color-flow duplex ultrasonography in, 57, 57-58
 - vascular surgery in, 125
- Venous thrombosis, intraurethral alprostadil in, 116
- Viagra. *See Sildenafil (Viagra).*
- Visual disturbance, sildenafil-related, 90t-91t, 92, 95-96
- Warfarin, 100
- Widower's syndrome, 33
- Yohimbine, 73, 101-102